New Medicare reform analysis featured in American Journal of Managed Care
During our transition, where to find information about:
- Our merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
According to new research by Avalere, sponsored by PAN, changes in standalone prescription drug plans (PDPs) and low-income subsidy (LIS) plans between 2023 and 2024 are shifting affordability for Medicare beneficiaries.
An article the American Journal of Managed Care looked at the findings from the new analysis, which examines 24 of the most used, single-source brand drugs across five therapeutic areas: pulmonary hypertension, multiple sclerosis, autoimmune disorders, asthma or chronic obstructive pulmonary disease, and anticoagulants. The analysis found that there was a 12% decrease in the number of PDPs offered in 2024 compared to those offered in 2023, impacting approximately 400,000 enrollees.
“While the Medicare Part D reforms included in the Inflation Reduction Act have great promise, this analysis reinforces the access and affordability challenges that will continue to face patients across the country,” said PAN Foundation President and CEO Kevin L. Hagan.